Clinical bottom line
Early initiation of novel oral selective cardiac myosin inhibitors represents a promising therapeutic approach for patients with restrictive cardiomyopathy (RCM), including those with cardiac amyloidosis, by targeting the fundamental contractile dysfunction. While these agents have demonstrated efficacy in related cardiomyopathies such as hypertrophic cardiomyopathy (HCM), their role in RCM remains putative and hypothesis-generating. Current evidence is largely extrapolated from studies in obstructive HCM and mechanistic insights, underscoring the need for dedicated clinical trials to validate safety, efficacy, and long-term outcomes in RCM populations.
What the evidence shows
Cardiac myosin inhibitors have emerged as a novel class of agents that directly modulate sarcomeric contractility by selectively inhibiting cardiac myosin ATPase activity, thereby reducing hypercontractility and myocardial energy consumption (Masri et al., 2022; Szczesna-Cordary et al., 2024). These agents have been primarily studied in obstructive hypertrophic cardiomyopathy, where meta-analyses of cardiac magnetic resonance imaging outcomes demonstrate favorable effects on cardiac structure and myocardial fibrosis (Lu et al., 2026). The mechanism of action suggests potential applicability to other cardiomyopathies characterized by diastolic dysfunction and restrictive physiology, such as RCM.
Restrictive cardiomyopathy, often caused by infiltrative diseases like cardiac amyloidosis, leads to stiff ventricles with impaired filling and preserved systolic function (Savli Gregor et al., 2013). Current treatments are limited and largely supportive. Given the pathophysiology involving abnormal sarcomeric function and myocardial stiffness, selective myosin inhibition could theoretically improve myocardial relaxation and reduce filling pressures.
Although direct clinical trial data in RCM are lacking, the biological rationale is supported by the success of myosin inhibitors in related cardiomyopathies and the mechanistic overlap in myocardial contractile abnormalities (Bittencourt et al., 2026). Early initiation of targeted therapies in cardiomyopathies has been associated with improved remodeling and outcomes (Kajimoto et al., 2007), suggesting that timely intervention with myosin inhibitors might alter disease trajectory in RCM.
Caveats and uncertainty
The evidence supporting the use of cardiac myosin inhibitors in restrictive cardiomyopathy is currently indirect and extrapolative. No randomized controlled trials have yet evaluated these agents specifically in RCM populations, including those with cardiac amyloidosis. The heterogeneity of RCM etiologies and the complex pathophysiology involving extracellular matrix expansion and infiltration may limit the efficacy of myosin inhibition alone.
Safety profiles established in HCM may not fully translate to RCM patients, who often have comorbidities and advanced disease stages. Potential adverse effects such as excessive negative inotropy or arrhythmogenesis require careful evaluation. Moreover, the impact on hard clinical endpoints such as mortality, hospitalization, and quality of life remains unknown in this context.
Imaging and biomarker endpoints used in HCM studies may not capture the full spectrum of RCM disease modification. Thus, cautious interpretation is warranted until dedicated clinical trials provide robust data.
How this may change practice
If validated in future clinical trials, early initiation of novel oral selective cardiac myosin inhibitors could represent a paradigm shift in the management of restrictive cardiomyopathy by addressing the underlying sarcomeric dysfunction rather than solely managing symptoms. This approach may complement existing therapies targeting amyloid deposition or fibrosis, potentially improving diastolic function, reducing heart failure symptoms, and delaying progression.
Clinicians should remain aware of ongoing research and emerging evidence in this area, particularly as new agents receive regulatory approval for broader cardiomyopathy indications. Multidisciplinary collaboration involving cardiologists, heart failure specialists, and amyloidosis experts will be essential to integrate these therapies safely and effectively.
At present, the use of cardiac myosin inhibitors in RCM should be considered investigational and limited to clinical trial settings or specialized centers with expertise in advanced cardiomyopathies.